US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Oncolytics Biotech Inc. - Common Stock
(NQ:
ONCY
)
0.4254
-0.0023 (-0.54%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oncolytics Biotech Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
December 01, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer
December 01, 2022
FDA Fast Track designation granted after presentation at the SITC 37th Annual Meeting demonstrating 69% objective response rate San Diego, CA and Calgary, AB – December 1, 2022 – Oncolytics Biotech®...
Via
FinancialNewsMedia
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
November 30, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END
Via
FinancialNewsMedia
Earnings Scheduled For August 11, 2022
↗
August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
Via
Benzinga
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
November 15, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech...
Via
FinancialNewsMedia
Topics
Death
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
November 14, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his...
Via
FinancialNewsMedia
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
November 10, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END
Via
FinancialNewsMedia
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study’s Pancreatic Cancer Cohort
November 10, 2022
One complete response (CR) and eight partial responses (PR) achieved in thirteen evaluable patients 69% objective response rate (ORR) is nearly three times greater than the average ORR of ~25% reported...
Via
FinancialNewsMedia
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
↗
November 09, 2022
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
Via
Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
↗
November 08, 2022
Gainers
Via
Benzinga
Recap: Oncolytics Biotech Q3 Earnings
↗
November 07, 2022
Oncolytics Biotech (NASDAQ:ONCY) reported its Q3 earnings results on Monday, November 7, 2022 at 08:03 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies
November 07, 2022
Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and...
Via
FinancialNewsMedia
Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
October 05, 2022
Interim results from the phase 1/2 GOBLET study’s pancreatic cancer cohort to be presented in a poster on November 11th and discussed during a key opinion leader webinar on November 14th at 10 a.m. ET...
Via
FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
↗
October 06, 2022
Upgrades
Via
Benzinga
Oncolytics Reports Partnering With Biopharma Industry Leaders To Fast-Track Immunotherapy Treatment
↗
June 02, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
October 05, 2022
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...
Via
FinancialNewsMedia
Topics
Death
A Preview Of Oncolytics Biotech's Earnings
↗
May 04, 2022
Oncolytics Biotech (NASDAQ:ONCY) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
May 04, 2022
Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study Statistically significant...
Via
FinancialNewsMedia
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
June 28, 2022
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent...
Via
FinancialNewsMedia
Oncolytics Expected To Announce Progress On New Glioblastoma Treatment This Spring
↗
March 15, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Recap: Oncolytics Biotech Q4 Earnings
↗
March 03, 2022
Oncolytics Biotech (NASDAQ:ONCY) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients
May 04, 2022
Palm Beach, FL – May 4, 2022 – FinancialNewsMedia.com News Commentary – Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years...
Via
FinancialNewsMedia
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
↗
March 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...
Via
Benzinga
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
April 14, 2022
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically...
Via
FinancialNewsMedia
Preview: Oncolytics Biotech's Earnings
↗
March 02, 2022
Oncolytics Biotech (NASDAQ:ONCY) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
↗
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
March 24, 2022
Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor...
Via
FinancialNewsMedia
This Biotech Company Reports Making Ground-Breaking Strides In Combating Solid Tumors
↗
February 23, 2022
Photo by National Cancer Institute on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing...
Via
Benzinga
Oncolytics Reports Foothold In Chinese Pharmaceutical Market With Latest Breast Cancer Clinical Trials
↗
February 16, 2022
Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Oncolytics...
Via
Benzinga
Earnings Scheduled For March 3, 2022
↗
March 03, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
